← Oncology Approval Tracker

FDA DECISION ·

Opdivo + Yervoy

nivolumab + ipilimumab · Bristol Myers Squibb

Accelerated approvalNew or expanded indicationHepatocellular carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Apr 11, 2025

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Patients with hepatocellular carcinoma previously treated with sorafenib.

LAMPGEN ANALYSIS

Why it matters

Introduced dual checkpoint blockade for this previously treated liver cancer population under accelerated approval.

What research teams should watch

Record prior sorafenib use and monitor liver function to distinguish immune toxicity from underlying disease.

PRIMARY RECORDS

Sources